一心堂(002727) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥4,086,535,700.64, representing a decrease of 4.62% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥18,941,635.48, an increase of 78.71% year-on-year, while net profit excluding non-recurring items was ¥9,935,344.15, down 78.04%[5]. - The company reported a basic earnings per share of ¥0.0324, an increase of 82.02% year-on-year[5]. - Total operating revenue for the current period is CNY 13,001,028,971.88, a decrease of 4.3% from CNY 13,589,430,513.51 in the previous period[26]. - Net profit for the current period is CNY 279,953,869.97, a decline of 8.7% compared to CNY 306,673,555.30 in the previous period[27]. - Earnings per share (EPS) for the current period is CNY 0.4587, down from CNY 0.4908 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥15,841,053,806.65, a decrease of 5.88% from the end of the previous year[5]. - The company's total assets decreased from 16,830,316,478.61 CNY to 15,841,053,806.65 CNY[24]. - The total liabilities decreased from 7,631,183,301.72 CNY to 6,979,005,378.72 CNY[24]. - Total liabilities amount to CNY 8,371,468,517.29, a decrease from CNY 9,177,027,604.21[25]. - Total equity attributable to shareholders of the parent company is CNY 7,317,083,552.48, down from CNY 7,491,014,022.79[25]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,432,091,712.35, reflecting a growth of 15.42%[5]. - Operating cash inflow for the current period was CNY 12,704,003,248.60, a decrease of 3.49% from CNY 13,165,397,205.14 in the previous period[28]. - Net cash flow from operating activities increased to CNY 1,432,091,712.35, up 15.43% from CNY 1,240,746,217.23 year-on-year[28]. - Cash inflow from investment activities totaled CNY 2,467,651,564.49, significantly higher than CNY 221,281,983.49 in the previous period[28]. - Cash inflow from financing activities was CNY 580,060,000.00, an increase from CNY 457,060,000.00 in the previous period[29]. - Net cash flow from financing activities was negative at CNY -1,139,973,371.69, an improvement from CNY -1,309,261,172.78 year-on-year[29]. Investments and Expenditures - The company increased its investment in other equity instruments by 272.86%, totaling ¥13,050,000.00, due to new investments and adjustments in existing holdings[9]. - The construction in progress increased by 210.73% to ¥111,198,725.40, driven by multiple ongoing projects including digital manufacturing bases[10]. - Cash paid for operating activities was CNY 11,271,911,536.25, a decrease from CNY 11,924,650,987.91 in the previous period[28]. - Total cash outflow for investment activities was CNY 2,417,100,285.50, compared to CNY 599,520,771.70 in the previous period[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,494[15]. - The largest shareholder, 阮鸿献, holds 31.12% of the shares, amounting to 182,245,290 shares[15]. - The company approved a cash dividend of 2 CNY per 10 shares, totaling 114,825,645 CNY (including tax) for the 2025 interim profit distribution[18]. Business Segments and Operations - The traditional Chinese medicine segment focuses on developing innovative products in the food and medicine integration field, enhancing product standardization and convenience[19]. - The first centralized healthcare center achieved breakeven within two years, with a second center under construction expected to open in the first half of 2026[20]. - The non-pharmaceutical business segment has completed the upgrade of 805 stores, with significant growth driven by the health and wellness category, maintaining high double-digit growth in the first three quarters of 2025[21].